产品
编 号：F425472
分子式：C8H8N2O3S
分子量：212.23
分子式：C8H8N2O3S
分子量：212.23
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
200mg
683
In-stock
500mg
询价
询价
结构图
CAS No: 68291-97-4
产品详情
生物活性：
Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy.
体内研究：
Zonisamide (40 mg/kg; i.p.; single daily for 14 days) prevents seizures in FeCl3-induced chronic amygdalar seizures model.?Zonisamide (14, 28, 56 mg/kg; i.p.; single daily for 6 weeks) alleviates cardiac hypertrophy and improved cardiac function in rats subjected to AAC (abdominal aortic constriction).?Zonisamide (14, 28, 56 mg/kg; i.p.; single daily for 6 weeks) upregulates Hrd1 expression and accelerates ERAD in the hearts of AAC rats.Animal Model:Male Wistar rats (200-250 g; FeCl3-induced chronic amygdalar seizures).
Dosage:40 mg/kg
Administration:Intraperitoneal injection; single daily for 14 days.
Result:Showed activity of anti-seizures.Significantly down-regulated GABA transporters GAT-1 in the hippocampus.
Animal Model:Adult male Sprague-Dawley rats (100-120 g; cardiac hypertrophy model).
Dosage:14, 28, 56 mg/kg
Administration:Intraperitoneal injection; single daily for 6 weeks.
Result:Significantly attenuated cardiac hypertrophy and fibrosis.Increased LV ejection fraction (EF), fractional shortening (FS) and E/A ratio.Markedly increased the expression of Hrd1 in the hearts of AAC rats.
体外研究：
Zonisamide (10, 50, 100, 200 μM; 24 h) increases viability of SH-SY5Y cells via an anti-apoptotic effect.?Zonisamide (100 μM; 24 h) shows neuroprotective effects in PD-cellular models. (PD: parkinson’s disease).?Zonisamide (100 μM; 24 h) reduces levels of proapoptotic molecules, and upregulates levels of MnSOD (MnSOD over-expression attenuates MPTP toxicity and protects cells from apoptosis).?Zonisamide (0.1, 0.3, 1 μM; 24 h) inhibits cardiac hypertrophy and fibrosis in vitro.?Zonisamide markedly increases the expression of Hrd1 in Ang II-treated NRCMs.
Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy.
体内研究：
Zonisamide (40 mg/kg; i.p.; single daily for 14 days) prevents seizures in FeCl3-induced chronic amygdalar seizures model.?Zonisamide (14, 28, 56 mg/kg; i.p.; single daily for 6 weeks) alleviates cardiac hypertrophy and improved cardiac function in rats subjected to AAC (abdominal aortic constriction).?Zonisamide (14, 28, 56 mg/kg; i.p.; single daily for 6 weeks) upregulates Hrd1 expression and accelerates ERAD in the hearts of AAC rats.Animal Model:Male Wistar rats (200-250 g; FeCl3-induced chronic amygdalar seizures).
Dosage:40 mg/kg
Administration:Intraperitoneal injection; single daily for 14 days.
Result:Showed activity of anti-seizures.Significantly down-regulated GABA transporters GAT-1 in the hippocampus.
Animal Model:Adult male Sprague-Dawley rats (100-120 g; cardiac hypertrophy model).
Dosage:14, 28, 56 mg/kg
Administration:Intraperitoneal injection; single daily for 6 weeks.
Result:Significantly attenuated cardiac hypertrophy and fibrosis.Increased LV ejection fraction (EF), fractional shortening (FS) and E/A ratio.Markedly increased the expression of Hrd1 in the hearts of AAC rats.
体外研究：
Zonisamide (10, 50, 100, 200 μM; 24 h) increases viability of SH-SY5Y cells via an anti-apoptotic effect.?Zonisamide (100 μM; 24 h) shows neuroprotective effects in PD-cellular models. (PD: parkinson’s disease).?Zonisamide (100 μM; 24 h) reduces levels of proapoptotic molecules, and upregulates levels of MnSOD (MnSOD over-expression attenuates MPTP toxicity and protects cells from apoptosis).?Zonisamide (0.1, 0.3, 1 μM; 24 h) inhibits cardiac hypertrophy and fibrosis in vitro.?Zonisamide markedly increases the expression of Hrd1 in Ang II-treated NRCMs.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备